| 31.98 -0.15 (-0.47%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.31 | 1-year : | 42.35 |
| Resists | First : | 34.51 | Second : | 36.25 |
| Pivot price | 33.39 |
|||
| Supports | First : | 31.7 | Second : | 26.37 |
| MAs | MA(5) : | 33.07 |
MA(20) : | 33.57 |
| MA(100) : | 33.37 |
MA(250) : | 33.27  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 13.6 |
D(3) : | 27.9 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 43.15 | Low : | 22.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VKTX ] has closed above bottom band by 8.1%. Bollinger Bands are 45% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 33.1 - 33.33 | 33.33 - 33.51 |
| Low: | 31.1 - 31.41 | 31.41 - 31.65 |
| Close: | 31.55 - 31.97 | 31.97 - 32.29 |
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Sat, 12 Sep 2026
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
Fri, 11 Sep 2026
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Fri, 11 Sep 2026
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Fri, 11 Sep 2026
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
Thu, 10 Sep 2026
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance UK
Wed, 09 Sep 2026
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 117 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 66.1 (%) |
| Shares Short | 22,290 (K) |
| Shares Short P.Month | 23,160 (K) |
| EPS | -4.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.9 % |
| Return on Equity (ttm) | -88.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -418 (M) |
| Levered Free Cash Flow | -231 (M) |
| PE Ratio | -6.85 |
| PEG Ratio | 0 |
| Price to Book value | 9.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|